The third line of treatment for metastatic prostate cancer patients: Option or strategy?
about
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trialsIs there still a place for docetaxel rechallenge in prostate cancer?Is it time for everolimus-based combination in castration-resistant prostate cancer?Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.
P2860
The third line of treatment for metastatic prostate cancer patients: Option or strategy?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The third line of treatment for metastatic prostate cancer patients: Option or strategy?
@en
type
label
The third line of treatment for metastatic prostate cancer patients: Option or strategy?
@en
prefLabel
The third line of treatment for metastatic prostate cancer patients: Option or strategy?
@en
P1476
The third line of treatment for metastatic prostate cancer patients: Option or strategy?
@en
P2093
Letizia Laera
Roberto Petrioli
P304
P356
10.1016/J.CRITREVONC.2015.04.010
P577
2015-05-21T00:00:00Z